Row | STUDYID | USUBJID | SITEID | RSSEQ | ASEQ | ITTFL | TRTP | PARAM | PARAMCD | PARAMN | PARCAT1 | VISIT | VISITNUM | AVISIT | AVISITN | RSDTC | ADT | ADY | RSORRES | RSORRESU | RSCBRFL | AVAL | DTYPE | ABLFL | COUNTRY | REGION1 | REGION1N |
1 | STUDYX | X-100-P0001 | 100 | 1 | 1 | Y | DRUG A + SOC | APCH1-Temperature - Rectal | APCH101 | 1 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 38.5-38.9 | C |
| 1 |
|
| USA | North America | 1 |
2 | STUDYX | X-100-P0001 | 100 | 2 | 2 | Y | DRUG A + SOC | APCH1-Mean Arterial Pressure | APCH102 | 2 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 110-129 | mmHg |
| 2 |
|
| USA | North America | 1 |
3 | STUDYX | X-100-P0001 | 100 | 3 | 3 | Y | DRUG A + SOC | APCH1-Heart Rate | APCH103 | 3 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 70-109 | beats/min |
| 0 |
|
| USA | North America | 1 |
4 | STUDYX | X-100-P0001 | 100 | 4 | 4 | Y | DRUG A + SOC | APCH1-Respiratory Rate | APCH104 | 4 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 25-34 | breaths/min |
| 1 |
|
| USA | North America | 1 |
5 | STUDYX | X-100-P0001 | 100 | 5 | 5 | Y | DRUG A + SOC | APCH1-Oxygenation: A-aDO2 | APCH105A | 5 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 |
|
| Y |
|
|
| USA | North America | 1 |
6 | STUDYX | X-100-P0001 | 100 | 6 | 6 | Y | DRUG A + SOC | APCH1-Oxygenation: PaO2 | APCH105B | 6 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 61-70 | mmHg |
| 1 |
|
| USA | North America | 1 |
7 | STUDYX | X-100-P0001 | 100 | 7 | 7 | Y | DRUG A + SOC | APCH1-Arterial pH | APCH106A | 7 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 7.15-7.24 |
|
| 3 |
|
| USA | North America | 1 |
8 | STUDYX | X-100-P0001 | 100 | 8 | 8 | Y | DRUG A + SOC | APCH1-Serum HCO3 | APCH106B | 8 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 |
|
| Y |
|
|
| USA | North America | 1 |
9 | STUDYX | X-100-P0001 | 100 | 9 | 9 | Y | DRUG A + SOC | APCH1-Serum Sodium | APCH107 | 9 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 150-154 | mmol/L |
| 1 |
|
| USA | North America | 1 |
10 | STUDYX | X-100-P0001 | 100 | 10 | 10 | Y | DRUG A + SOC | APCH1-Serum Potassium | APCH108 | 10 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 3.5-5.4 | mmol/L |
| 0 |
|
| USA | North America | 1 |
11 | STUDYX | X-100-P0001 | 100 | 11 | 11 | Y | DRUG A + SOC | APCH1-Serum Creatinine | APCH109 | 11 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | <0.6 | mg/dL |
| 2 |
|
| USA | North America | 1 |
12 | STUDYX | X-100-P0001 | 100 | 12 | 12 | Y | DRUG A + SOC | APCH1-Hematocrit | APCH110 | 12 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 20-29.9 | % |
| 2 |
|
| USA | North America | 1 |
13 | STUDYX | X-100-P0001 | 100 | 13 | 13 | Y | DRUG A + SOC | APCH1-White Blood Count | APCH111 | 13 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 20-39.9 | 10^9/L |
| 2 |
|
| USA | North America | 1 |
14 | STUDYX | X-100-P0001 | 100 | 14 | 14 | Y | DRUG A + SOC | APCH1-15 Minus Glasgow Coma Score | APCH112 | 14 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 3 |
|
| 3 |
|
| USA | North America | 1 |
15 | STUDYX | X-100-P0001 | 100 | 15 | 15 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score | APCH113 | 15 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 18 |
|
| 18 |
|
| USA | North America | 1 |
16 | STUDYX | X-100-P0001 | 100 |
| 16 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score - Analysis | APCH1TPS | 16 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 |
|
|
| 18 |
| Y | USA | North America | 1 |
17 | STUDYX | X-100-P0001 | 100 | 16 | 17 | Y | DRUG A + SOC | APCH1-B: Age Points | APCH114 | 17 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 45-54 | YEARS |
| 2 |
|
| USA | North America | 1 |
18 | STUDYX | X-100-P0001 | 100 | 17 | 18 | Y | DRUG A + SOC | APCH1-C: Chronic Health Points | APCH115 | 18 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | for elective postoperative patients |
|
| 2 |
|
| USA | North America | 1 |
19 | STUDYX | X-100-P0001 | 100 | 18 | 19 | Y | DRUG A + SOC | APCH1-Total APACHE II Score | APCH116 | 19 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 | 22 |
|
| 22 |
|
| USA | North America | 1 |
20 | STUDYX | X-100-P0001 | 100 |
| 20 | Y | DRUG A + SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-06-29 | 29JUN201429JUN2020 | 1 |
|
|
| 22 |
| Y | USA | North America | 1 |
21 | STUDYX | X-100-P0001 | 100 | 19 | 21 | Y | DRUG A + SOC | APCH1-Temperature - Rectal | APCH101 | 1 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 38.5-38.9 | C |
| 1 |
|
| USA | North America | 1 |
22 | STUDYX | X-100-P0001 | 100 | 20 | 22 | Y | DRUG A + SOC | APCH1-Mean Arterial Pressure | APCH102 | 2 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 70–109 | mmHg |
| 0 |
|
| USA | North America | 1 |
23 | STUDYX | X-100-P0001 | 100 | 21 | 23 | Y | DRUG A + SOC | APCH1-Heart Rate | APCH103 | 3 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 70-109 | beats/min |
| 0 |
|
| USA | North America | 1 |
24 | STUDYX | X-100-P0001 | 100 | 22 | 24 | Y | DRUG A + SOC | APCH1-Respiratory Rate | APCH104 | 4 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 25-34 | breaths/min |
| 1 |
|
| USA | North America | 1 |
25 | STUDYX | X-100-P0001 | 100 | 23 | 25 | Y | DRUG A + SOC | APCH1-Oxygenation: A-aDO2 | APCH105A | 5 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 |
|
| Y |
|
|
| USA | North America | 1 |
26 | STUDYX | X-100-P0001 | 100 | 24 | 26 | Y | DRUG A + SOC | APCH1-Oxygenation: PaO2 | APCH105B | 6 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 61-70 | mmHg |
| 1 |
|
| USA | North America | 1 |
27 | STUDYX | X-100-P0001 | 100 | 25 | 27 | Y | DRUG A + SOC | APCH1-Arterial pH | APCH106A | 7 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 7.25-7.32 |
|
| 2 |
|
| USA | North America | 1 |
28 | STUDYX | X-100-P0001 | 100 | 26 | 28 | Y | DRUG A + SOC | APCH1-Serum HCO3 | APCH106B | 8 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 |
|
| Y |
|
|
| USA | North America | 1 |
29 | STUDYX | X-100-P0001 | 100 | 27 | 29 | Y | DRUG A + SOC | APCH1-Serum Sodium | APCH107 | 9 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 150-154 | mmol/L |
| 1 |
|
| USA | North America | 1 |
30 | STUDYX | X-100-P0001 | 100 | 28 | 30 | Y | DRUG A + SOC | APCH1-Serum Potassium | APCH108 | 10 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 3.5-5.4 | mmol/L |
| 0 |
|
| USA | North America | 1 |
31 | STUDYX | X-100-P0001 | 100 | 29 | 31 | Y | DRUG A + SOC | APCH1-Serum Creatinine | APCH109 | 11 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 0.6-1.4 | mg/dL |
| 0 |
|
| USA | North America | 1 |
32 | STUDYX | X-100-P0001 | 100 | 30 | 32 | Y | DRUG A + SOC | APCH1-Hematocrit | APCH110 | 12 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 20-29.9 | % |
| 2 |
|
| USA | North America | 1 |
33 | STUDYX | X-100-P0001 | 100 | 31 | 33 | Y | DRUG A + SOC | APCH1-White Blood Count | APCH111 | 13 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 15-19.9 | 10^9/L |
| 1 |
|
| USA | North America | 1 |
34 | STUDYX | X-100-P0001 | 100 | 32 | 34 | Y | DRUG A + SOC | APCH1-15 Minus Glasgow Coma Score | APCH112 | 14 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 1 |
|
| 1 |
|
| USA | North America | 1 |
35 | STUDYX | X-100-P0001 | 100 | 33 | 35 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score | APCH113 | 15 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 10 |
|
| 10 |
|
| USA | North America | 1 |
36 | STUDYX | X-100-P0001 | 100 |
| 36 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score - Analysis | APCH1TPS | 16 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 |
|
|
| 10 |
|
| USA | North America | 1 |
37 | STUDYX | X-100-P0001 | 100 | 34 | 37 | Y | DRUG A + SOC | APCH1-B: Age Points | APCH114 | 17 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 45-54 | YEARS |
| 2 |
|
| USA | North America | 1 |
38 | STUDYX | X-100-P0001 | 100 | 35 | 38 | Y | DRUG A + SOC | APCH1-C: Chronic Health Points | APCH115 | 18 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | for elective postoperative patients |
|
| 2 |
|
| USA | North America | 1 |
39 | STUDYX | X-100-P0001 | 100 | 36 | 39 | Y | DRUG A + SOC | APCH1-Total APACHE II Score | APCH116 | 19 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 | 14 |
|
| 14 |
|
| USA | North America | 1 |
40 | STUDYX | X-100-P0001 | 100 |
| 40 | Y | DRUG A + SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | DAY 7 | 7 | Day 7 | 7 | 20142020-07-05 | 05JUL201405JUL2020 | 7 |
|
|
| 14 |
|
| USA | North America | 1 |
41 | STUDYX | X-100-P0001 | 100 | 37 | 41 | Y | DRUG A + SOC | APCH1-Temperature - Rectal | APCH101 | 1 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 36-38.4 | C |
| 0 |
|
| USA | North America | 1 |
42 | STUDYX | X-100-P0001 | 100 | 38 | 42 | Y | DRUG A + SOC | APCH1-Mean Arterial Pressure | APCH102 | 2 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 70–109 | mmHg |
| 0 |
|
| USA | North America | 1 |
43 | STUDYX | X-100-P0001 | 100 | 39 | 43 | Y | DRUG A + SOC | APCH1-Heart Rate | APCH103 | 3 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 70-109 | beats/min |
| 0 |
|
| USA | North America | 1 |
44 | STUDYX | X-100-P0001 | 100 | 40 | 44 | Y | DRUG A + SOC | APCH1-Respiratory Rate | APCH104 | 4 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 12–24 | breaths/min |
| 0 |
|
| USA | North America | 1 |
45 | STUDYX | X-100-P0001 | 100 | 41 | 45 | Y | DRUG A + SOC | APCH1-Oxygenation: A-aDO2 | APCH105A | 5 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 |
|
| Y |
|
|
| USA | North America | 1 |
46 | STUDYX | X-100-P0001 | 100 | 42 | 46 | Y | DRUG A + SOC | APCH1-Oxygenation: PaO2 | APCH105B | 6 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 61-70 | mmHg |
| 1 |
|
| USA | North America | 1 |
47 | STUDYX | X-100-P0001 | 100 | 43 | 47 | Y | DRUG A + SOC | APCH1-Arterial pH | APCH106A | 7 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 7.33-7.49 |
|
| 0 |
|
| USA | North America | 1 |
48 | STUDYX | X-100-P0001 | 100 | 44 | 48 | Y | DRUG A + SOC | APCH1-Serum HCO3 | APCH106B | 8 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 |
|
| Y |
|
|
| USA | North America | 1 |
49 | STUDYX | X-100-P0001 | 100 | 45 | 49 | Y | DRUG A + SOC | APCH1-Serum Sodium | APCH107 | 9 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 130-149 | mmol/L |
| 0 |
|
| USA | North America | 1 |
50 | STUDYX | X-100-P0001 | 100 | 46 | 50 | Y | DRUG A + SOC | APCH1-Serum Potassium | APCH108 | 10 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 3.5-5.4 | mmol/L |
| 0 |
|
| USA | North America | 1 |
51 | STUDYX | X-100-P0001 | 100 | 47 | 51 | Y | DRUG A + SOC | APCH1-Serum Creatinine | APCH109 | 11 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 0.6-1.4 | mg/dL |
| 0 |
|
| USA | North America | 1 |
52 | STUDYX | X-100-P0001 | 100 | 48 | 52 | Y | DRUG A + SOC | APCH1-Hematocrit | APCH110 | 12 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 46-49.9 | % |
| 1 |
|
| USA | North America | 1 |
53 | STUDYX | X-100-P0001 | 100 | 49 | 53 | Y | DRUG A + SOC | APCH1-White Blood Count | APCH111 | 13 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 3-14.9 | 10^9/L |
| 0 |
|
| USA | North America | 1 |
54 | STUDYX | X-100-P0001 | 100 | 50 | 54 | Y | DRUG A + SOC | APCH1-15 Minus Glasgow Coma Score | APCH112 | 14 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 0 |
|
| 0 |
|
| USA | North America | 1 |
55 | STUDYX | X-100-P0001 | 100 | 51 | 55 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score | APCH113 | 15 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 2 |
|
| 2 |
|
| USA | North America | 1 |
56 | STUDYX | X-100-P0001 | 100 |
| 56 | Y | DRUG A + SOC | APCH1-A: Total Acute Physiology Score - Analysis | APCH1TPS | 16 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 |
|
|
| 2 |
|
| USA | North America | 1 |
57 | STUDYX | X-100-P0001 | 100 | 52 | 57 | Y | DRUG A + SOC | APCH1-B: Age Points | APCH114 | 17 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 45-54 | YEARS |
| 2 |
|
| USA | North America | 1 |
58 | STUDYX | X-100-P0001 | 100 | 53 | 58 | Y | DRUG A + SOC | APCH1-C: Chronic Health Points | APCH115 | 18 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | for elective postoperative patients |
|
| 2 |
|
| USA | North America | 1 |
59 | STUDYX | X-100-P0001 | 100 | 54 | 59 | Y | DRUG A + SOC | APCH1-Total APACHE II Score | APCH116 | 19 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 | 6 |
|
| 6 |
|
| USA | North America | 1 |
60 | STUDYX | X-100-P0001 | 100 |
| 60 | Y | DRUG A + SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | DAY 15 | 15 | Day 15 (Day of Discharge) | 15 | 20142020-07-13 | 13JUL201413JUL2020 | 15 |
|
|
| 6 |
|
| USA | North America | 1 |
61 | STUDYX | X-200-P0002 | 200 | 1 | 1 | Y | SOC | APCH1-Temperature - Rectal | APCH101 | 1 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 38.5-38.9 | C |
| 1 |
|
| GBR | Non-North America | 0 |
62 | STUDYX | X-200-P0002 | 200 | 2 | 2 | Y | SOC | APCH1-Mean Arterial Pressure | APCH102 | 2 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 110-129 | mmHg |
| 2 |
|
| GBR | Non-North America | 0 |
63 | STUDYX | X-200-P0002 | 200 | 3 | 3 | Y | SOC | APCH1-Heart Rate | APCH103 | 3 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 70-109 | beats/min |
| 0 |
|
| GBR | Non-North America | 0 |
64 | STUDYX | X-200-P0002 | 200 | 4 | 4 | Y | SOC | APCH1-Respiratory Rate | APCH104 | 4 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | >=50 | breaths/min |
| 4 |
|
| GBR | Non-North America | 0 |
65 | STUDYX | X-200-P0002 | 200 | 5 | 5 | Y | SOC | APCH1-Oxygenation: A-aDO2 | APCH105A | 5 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 |
|
| Y |
|
|
| GBR | Non-North America | 0 |
66 | STUDYX | X-200-P0002 | 200 | 6 | 6 | Y | SOC | APCH1-Oxygenation: PaO2 | APCH105B | 6 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 61-70 | mmHg |
| 1 |
|
| GBR | Non-North America | 0 |
67 | STUDYX | X-200-P0002 | 200 | 7 | 7 | Y | SOC | APCH1-Arterial pH | APCH106A | 7 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | <7.15 |
|
| 4 |
|
| GBR | Non-North America | 0 |
68 | STUDYX | X-200-P0002 | 200 | 8 | 8 | Y | SOC | APCH1-Serum HCO3 | APCH106B | 8 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 |
|
| Y |
|
|
| GBR | Non-North America | 0 |
69 | STUDYX | X-200-P0002 | 200 | 9 | 9 | Y | SOC | APCH1-Serum Sodium | APCH107 | 9 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 150-154 | mmol/L |
| 1 |
|
| GBR | Non-North America | 0 |
70 | STUDYX | X-200-P0002 | 200 | 10 | 10 | Y | SOC | APCH1-Serum Potassium | APCH108 | 10 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 3.5-5.4 | mmol/L |
| 0 |
|
| GBR | Non-North America | 0 |
71 | STUDYX | X-200-P0002 | 200 | 11 | 11 | Y | SOC | APCH1-Serum Creatinine | APCH109 | 11 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | <0.6 | mg/dL |
| 2 |
|
| GBR | Non-North America | 0 |
72 | STUDYX | X-200-P0002 | 200 | 12 | 12 | Y | SOC | APCH1-Hematocrit | APCH110 | 12 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 20-29.9 | % |
| 2 |
|
| GBR | Non-North America | 0 |
73 | STUDYX | X-200-P0002 | 200 | 13 | 13 | Y | SOC | APCH1-White Blood Count | APCH111 | 13 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | >=40 | 10^9/L |
| 4 |
|
| GBR | Non-North America | 0 |
74 | STUDYX | X-200-P0002 | 200 | 14 | 14 | Y | SOC | APCH1-15 Minus Glasgow Coma Score | APCH112 | 14 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 3 |
|
| 3 |
|
| GBR | Non-North America | 0 |
75 | STUDYX | X-200-P0002 | 200 | 15 | 15 | Y | SOC | APCH1-A: Total Acute Physiology Score | APCH113 | 15 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 24 |
|
| 24 |
|
| GBR | Non-North America | 0 |
76 | STUDYX | X-200-P0002 | 200 |
| 16 | Y | SOC | APCH1-A: Total Acute Physiology Score - Analysis | APCH1TPS | 16 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 |
|
|
| 24 |
| Y | GBR | Non-North America | 0 |
77 | STUDYX | X-200-P0002 | 200 | 16 | 17 | Y | SOC | APCH1-B: Age Points | APCH114 | 17 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 65-74 | YEARS |
| 5 |
|
| GBR | Non-North America | 0 |
78 | STUDYX | X-200-P0002 | 200 | 17 | 18 | Y | SOC | APCH1-C: Chronic Health Points | APCH115 | 18 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | for elective postoperative patients |
|
| 2 |
|
| GBR | Non-North America | 0 |
79 | STUDYX | X-200-P0002 | 200 | 18 | 19 | Y | SOC | APCH1-Total APACHE II Score | APCH116 | 19 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 | 31 |
|
| 31 |
|
| GBR | Non-North America | 0 |
80 | STUDYX | X-200-P0002 | 200 |
| 20 | Y | SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II | SCREENING | 1 | Baseline | 0 | 20142020-08-04 | 04AUG201404AUG2020 | -1 |
|
|
| 31 |
| Y | GBR | Non-North America | 0 |
81 | STUDYX | X-200-P0002 | 200 |
| 21 | Y | SOC | APCH1-Total APACHE II Score - Analysis | APCH1TS | 20 | APACHE II |
|
| Day 15 (Day of Discharge) | 15 |
| 09AUG201409AUG2020 | 5 |
|
|
| 38 | WOC |
| GBR | Non-North America | 0 |